Form 4: Lippis Daniel J. reports multiple insider transactions in EW

Rhea-AI Filing Summary

Lippis Daniel J. reported multiple insider transaction types in a Form 4 filing for EW. The filing lists transactions totaling 13,276 shares at a weighted average price of $75.87 per share. Following the reported transactions, holdings were 34,366 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lippis Daniel J.

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CA 92614

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, TAVR

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		A		12,820(1)	A	$0.0000	34,821.9103	D
Common Stock	02/16/2026		F		258	D	$75.87	34,563.9103	D
Common Stock	02/17/2026		F		198	D	$75.87	34,365.9103	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These restricted stock units were granted on February 12, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did EW executive Daniel J. Lippis report?

Daniel J. Lippis reported receiving 12,820 Edwards Lifesciences common shares via a restricted stock unit grant and disposing of 456 shares in tax-withholding transactions at $75.87 per share, leaving him with direct beneficial ownership of about 34,366 shares.

Was the Edwards Lifesciences (EW) insider activity a stock sale?

The filing shows tax-withholding dispositions, not open-market sales. A total of 456 shares were delivered at $75.87 per share to satisfy tax obligations related to an equity award, while the executive’s overall share ownership remained substantial afterward.

How many Edwards Lifesciences (EW) shares did Daniel J. Lippis acquire?

He acquired 12,820 shares of Edwards Lifesciences common stock at $0.0000 per share through a restricted stock unit grant. These units vest in four equal annual installments beginning one year after the February 12, 2026 grant date.

What is the vesting schedule for the EW restricted stock units granted?

The restricted stock units granted on February 12, 2026 vest and become exercisable in four equal annual installments, starting one year after the grant date. This structure ties continued service at Edwards Lifesciences to the gradual delivery of common shares.

How many EW shares does the reporting person own after the Form 4 transactions?

After the reported grant and tax-withholding dispositions, Daniel J. Lippis directly beneficially owned approximately 34,365.9103 shares of Edwards Lifesciences common stock, reflecting his remaining stake following the equity compensation-related transactions.

What role does Daniel J. Lippis hold at Edwards Lifesciences (EW)?

Daniel J. Lippis is an officer of Edwards Lifesciences with the title CVP, TAVR. His Form 4 filing reflects changes in his beneficial ownership of company common stock resulting from a restricted stock unit grant and associated tax-withholding share dispositions.